Paper Details

  1. Home
  2. Paper Details

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.

Author: AuroraSheena K, DodickDavid W, FergusonMargaret B, GoadsbyPeter J, MartinezJames M, OakesTina M, SkljarevskiVladimir, ZhangQi

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Galcanezumab showed onset of efficacy within 1 week in a majority of patients with episodic migraine and patients receiving galcanezumab were twice more likely to maintain responses than placebo patients. Early non-responders may respond by month 2 or month 3.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND OBJECTIVE: As new migraine prevention treatments are developed, the onset of a preventive effect, how long it is maintained and whether patients initially non-responsive develop clinically meaningful responses with continued treatment can be assessed. METHODS: Analyses were conducted...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691875/

データ提供：米国国立医学図書館（NLM）

Galcanezumab for Migraine Prevention: Exploring the Onset and Duration of Efficacy

Migraine, a debilitating neurological disorder, significantly impacts the lives of millions worldwide. This research investigates the effectiveness of galcanezumab, a monoclonal antibody, for preventing episodic migraine. The authors conducted a post-hoc analysis of a clinical trial to assess the onset of galcanezumab's preventive effect, the duration of response, and the possibility of delayed response in initially non-responsive patients. Their findings demonstrate that galcanezumab exhibits rapid onset of action, with a significant reduction in migraine days observed within the first week of treatment. The study also found that a considerable proportion of patients maintained their response over time, while some initially non-responders experienced improvement with continued treatment.

A Promising New Frontier in Migraine Prevention: The Promise of Galcanezumab

This research sheds light on the potential of galcanezumab as a valuable tool for migraine prevention. The study's findings, showing a rapid onset of action and sustained efficacy, suggest that galcanezumab could offer significant benefits for individuals struggling with episodic migraine. These results provide hope for more effective and personalized treatment options for this debilitating disorder.

Navigating Migraine Management: A Personalized Approach

This research emphasizes the importance of a personalized approach to migraine management. The study's findings highlight the variability in response to galcanezumab, emphasizing the need for individualized treatment plans. Understanding the onset and duration of efficacy allows clinicians to tailor treatment strategies to maximize the benefits for each patient. This personalized approach is crucial for optimizing migraine management and improving patient outcomes.

Dr.Camel's Conclusion

Just as a desert traveler seeks respite from the relentless sun, individuals with migraine seek relief from the debilitating pain and disruption it causes. This research offers hope for a more effective and personalized approach to migraine management, exploring the potential of galcanezumab to provide a much-needed oasis of calm.

Date :
  1. Date Completed 2020-03-17
  2. Date Revised 2020-03-17
Further Info :

Pubmed ID

31004075

DOI: Digital Object Identifier

PMC6691875

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.